Table 2.
GMTs and fold increase in GMT for influenza A/H3N2, A/H1N1, and B strains in RA patients treated with Kampo formulae before and after administration of influenza vaccines.
| Total | Without MTX group* | With MTX group** | |
|---|---|---|---|
| GMT, mean ± SD | |||
| A/H1N1 strain | |||
| Baseline | 12.1 ± 14.0 | 11.0 ± 12.1 | 14.1 ± 15.0 |
| 4 weeks later | 78.8 ±119.7 | 39.6 ± 39.3 | 115.9 ± 148.8 |
| A/H3N2 strain | |||
| Baseline | 13.5 ±13.9 | 16.0 ±19.7 | 11.7 ±10.2 |
| 4 weeks later | 35.7 ±33.6 | 33.1 ± 21.8 | 39.1 ± 40.2 |
| B strain | |||
| Baseline | 12.8 ±10.3 | 13.9 ±9.2 | 11.4 ±11.5 |
| 4 weeks later | 27.3 ±27.8 | 22.8 ± 19.2 | 31.4 ±34.0 |
| Fold increase, mean (range) | |||
| A/H1N1 strain | 6.5 (1 to 64) | 3.6 (1 to 16) | 8.2 (1 to 64) |
| A/H3N2 strain | 2.6 (1 to 16) | 2.1 (1 to 8) | 3.3 (1 to 16) |
| B strain | 2.1 (1 to 16) | 1.6 (1 to 4) | 2.7 (1 to 16) |
*Without MTX group: patients treated with classical DMARDs alone. Patients treated with tacllolimus were excluded. **with MTX group: patients treated with MTX, but not biologics.